Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Ando

Showing results (201-210 of 241) with videos related to

Pageof 25
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 22, 2022
[Management of Chronic Kidney Disease in Cancer Survivors]Chihiro Kondoh, Kenji Ishikura, Satoko Ichioka, et al.
International Journal of Cancer|July 9, 2020
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumorsYoshihiro Nishida, Hiroshi Urakawa, Robert Nakayama, et al.
Cancer Science|April 3, 2008
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1Ken-ichi Fujita, Wataru Yamamoto, Shoji Endo, et al.
Cardio-Oncology (London, England)|July 7, 2021
Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective reviewShingo Kazama, Ryota Morimoto, Yuki Kimura, et al.
Cancer Science|May 15, 2021
Guidelines for clinical evaluation of anti-cancer drugsHironobu Minami, Naomi Kiyota, Shiro Kimbara, et al.
Cancer Chemotherapy and Pharmacology|October 20, 2010
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancerYu Sunakawa, Wataru Ichikawa, Ken-Ichi Fujita, et al.
Biological & Pharmaceutical Bulletin|November 5, 2008
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)Ken-ichi Fujita, Fumio Nagashima, Wataru Yamamoto, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2010
Delayed elimination of SN-38 in cancer patients with severe renal failureKen-ichi Fujita, Yu Sunakawa, Keisuke Miwa, et al.
Scientific Reports|February 24, 2019
An automated microliter-scale high-throughput screening system (MSHTS) for real-time monitoring of protein aggregation using quantum-dot nanoprobesRina Sasaki, Reina Tainaka, Yuichi Ando, et al.
Journal of Geriatric Oncology|June 1, 2026
Six key elements for effective coordination in home-based care for older adults with cancer in Japan: A qualitative interview studyAyumu Matsuoka, Misaki Ayata, Kiyomi Tanno, et al.
Pageof 25

Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 22, 2022
[Management of Chronic Kidney Disease in Cancer Survivors]Chihiro Kondoh, Kenji Ishikura, Satoko Ichioka, et al.
International Journal of Cancer|July 9, 2020
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumorsYoshihiro Nishida, Hiroshi Urakawa, Robert Nakayama, et al.
Cancer Science|April 3, 2008
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1Ken-ichi Fujita, Wataru Yamamoto, Shoji Endo, et al.
Cardio-Oncology (London, England)|July 7, 2021
Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective reviewShingo Kazama, Ryota Morimoto, Yuki Kimura, et al.
Cancer Science|May 15, 2021
Guidelines for clinical evaluation of anti-cancer drugsHironobu Minami, Naomi Kiyota, Shiro Kimbara, et al.
Cancer Chemotherapy and Pharmacology|October 20, 2010
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancerYu Sunakawa, Wataru Ichikawa, Ken-Ichi Fujita, et al.
Biological & Pharmaceutical Bulletin|November 5, 2008
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)Ken-ichi Fujita, Fumio Nagashima, Wataru Yamamoto, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 29, 2010
Delayed elimination of SN-38 in cancer patients with severe renal failureKen-ichi Fujita, Yu Sunakawa, Keisuke Miwa, et al.
Scientific Reports|February 24, 2019
An automated microliter-scale high-throughput screening system (MSHTS) for real-time monitoring of protein aggregation using quantum-dot nanoprobesRina Sasaki, Reina Tainaka, Yuichi Ando, et al.
Journal of Geriatric Oncology|June 1, 2026
Six key elements for effective coordination in home-based care for older adults with cancer in Japan: A qualitative interview studyAyumu Matsuoka, Misaki Ayata, Kiyomi Tanno, et al.
Pageof 25